Colistin-resistant bacteria require fatty acid synthesis to maintain cell envelope homeostasis; disrupting fatty acid biosynthesis leads to the remodelling of phospholipid composition and decreases the fluidity of the cell envelope. Inhibitors of fatty acid biosynthesis resensitize bacteria to colistin, allowing for the treatment of colistin-resistant bacterial infections in mice.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu, Y.-Y. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161–168 (2016). This paper reports the emergence of the first plasmid-mediated colistin resistance gene, mcr-1.
Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17, 141–155 (2019). This review article presents the role of combination therapies in extending the clinical use of antibiotics.
Lepak, A. J., Wang, W. & Andes, D. R. Pharmacodynamic evaluation of MRX-8, a novel polymyxin, in the neutropenic mouse thigh and lung infection models against Gram-negative pathogens. Antimicrob. Agents Chemother. 64, e01517-20 (2020). This paper presents in vivo efficacy and pharmacokinetics of a less toxic polymyxin derivative.
Roberts, K. D. et al. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nat. Commun. 13, 1625 (2022). This paper reports the systematic optimization of the polymyxin scaffold to improve safety and efficacy, resulting in the clinical candidate F365 (QPX9003).
Hood, M. I., Becker, K. W., Roux, C. M., Dunman, P. M. & Skaar, E. P. Genetic determinants of intrinsic colistin tolerance in Acinetobacter baumannii. Infect. Immun. 81, 542–551 (2013). This article presents the role of biotin biosynthesis in response to colistin treatment.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Carfrae, L. A. et al. Inhibiting fatty acid synthesis overcomes colistin resistance. Nat. Microbiol. https://doi.org/10.1038/s41564-023-01369-z (2023).
Rights and permissions
About this article
Cite this article
Inhibitors of fatty acid synthesis counter resistance to last-resort antibiotic colistin. Nat Microbiol 8, 1006–1007 (2023). https://doi.org/10.1038/s41564-023-01384-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41564-023-01384-0
